Abstract
The aim of the present guidance paper was to update the previous ENETS guidelines on well-differentiated gastric and duodenal neuroendocrine tumours (NETs), providing practical guidance for specialists in the diagnosis and management of gastroduodenal NETs. Type II gastric NETs, neuroendocrine carcinomas (NECs), and functioning duodenal NETs are not covered, since they will be discussed in other ENETS guidance papers.
| Original language | English |
|---|---|
| Article number | e13306 |
| Journal | Journal of Neuroendocrinology |
| Volume | 35 |
| Issue number | 8 |
| Early online date | 20 May 2023 |
| DOIs | |
| Publication status | Published - Aug 2023 |
Bibliographical note
Funding Information:Participants of the ENETS Guidance Paper Consensus Meeting – 13 October 2022. Bartsch, D. K. (Department of Visceral-, Thoracic- and Vascular Surgery Philipps-University Marburg, Marburg, Germany); Capdevila, J. (Medical Oncology Department, Gastrointestinal and Endocrine Unit, Vall d'Hebron University Hospital, Barcelona, Spain); Caplin, M. (Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital and University College London, London, UK); Castaño, J. P. (Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain); Couvelard, A. (Pathology Department, Bichat Hospital, AP-HP and Université Paris Cité, Paris, France); De Mestier L. (Beaujon Hospital, Université Paris-Cité, Pancreatology and Digestive Oncology, Paris, France); Denecke, T. (Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Leipzig, Leipzig, Germany); Fazio, N. (Division of Gastrointestinal Medical Oncology and neuroendocrine tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy); Garcia-Carbonero, R. (Department of Oncology, Hospital Universitario Doce de Octubre, Imas12, UCM, Madrid, Spain); Hofland, J. (Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands); Kaltsas, G. (1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece); Kjaer, A. (Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark); Knigge, U. (Departments of Surgery and Clinical Endocrinology, ENETS Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark); Koumarianou A. (National and Kapodistrian University of Athens, Haematology Oncology Unit, 4th Department of Internal Medicine, Athens, Greece); Pavel, M. (Department of Medicine 1, Universitätsklinikum Erlangen, Erlangen, Germany); Rindi, G. (Section of Anatomic Pathology, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore/Unit of Head and Neck, Thoracic and Endocrine Pathology, Department of Woman and Child Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia/Roma European Neuroendocrine Tumour Society (ENETS) Center of Excellence, Rome, Italy); Santos A. P. (Endocrinology Department, Endocrine Tumours Clinic, Precancerous Lesions and Early Cancer Management Group, RISE@CI-IPO (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal); Srirajaskanthan R. (Neuroendocrine Tumour Unit, Kings College Hospital/Department of Gastroenterology, Hambleden Wing, Kings College Hospital, London, UK); Tiensuu Janson, E. (Department of Medical Sciences, Endocrine Oncology, Medical Faculty, Uppsala Universitet, Uppsala, Sweden); Toumpanakis, C. (Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital and University College London, London, UK); Walter, T. (Department of Medical Oncology, Hôpital Edouard Herriot, Lyon, France).
Funding Information:
D. Mark Pritchard received funding for consultancy, lectures and conference attendance from Ipsen, Advanced Accelerator Applications and Mayoly Spindler laboratories and research funding to investigate the role of netazepide in type I gastric NETs from Trio Medicines Ltd. John Ramage received research funding from Novartis and Ipsen.
Publisher Copyright:
© 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
